Switzerland's MoonLake Q3 net loss widens as R&D costs rise

What happened

MoonLake Immunotherapeutics reported a third-quarter net loss of $79.55 as research and development expenses rose, mainly because of milestone license fees tied to an expected regulatory milestone. The company submitted a Biologics License Application for sonelokimab to the FDA for hidradenitis suppurativa.

Confirmed

Global impact / market context

Higher research and development costs widened the quarterly loss, while the milestone fees are tied to progress toward regulatory review. If the FDA accepts and later approves the application, the planned US launch could create sales; delays or rejection would postpone that potential revenue.

Analyst inference

The company’s reported cash balance gives it funding to continue development, while research and development spending tied to regulatory milestones contributes to its costs. The FDA’s decision on whether to accept the application and any later approval will shape the timing of a potential US launch and related commercial spending.

Analyst inference

What to watch

1. Watch for the FDA’s decision on whether it accepts the sonelokimab application for review, which MoonLake expects by the end of November 2026. Confirmed
2. The company anticipates a possible US commercial launch in the second half of 2027, but that plan depends on FDA approval. Confirmed
3. Track research and development spending and cash available against the stated mid-2028 funding runway; continued costs could shorten the time available to reach a launch. Analyst inference

Evidence

• Original source link unavailable